Davis Polk Advises Calyxt, Inc. on Its Initial Public Offering

Davis Polk advised Calyxt, Inc. in connection with its initial public offering of 8,050,000 shares of its common stock, including 1,050,000 shares of common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. The offering resulted in approximately $64.4 million of proceeds to Calyxt, before deducting underwriting discounts and estimated offering expenses. Calyxt’s common stock is listed on the NASDAQ Global Market under the symbol “CLXT.”

Based in New Brighton, Minnesota, Calyxt is a consumer-centric, food- and agriculture focused company. By combining its leading gene-editing technology and technical expertise with its innovative commercial strategy, Calyxt is pioneering a paradigm shift to deliver healthier specialty food ingredients for consumers and agriculturally advantageous crop traits for farmers. Calyxt is a subsidiary of Cellectis S.A., a gene-editing company focused on developing products in the field of immuno-oncology.

The Davis Polk team corporate team included partners Richard D. Truesdell, Jr. and Derek Dostal and associates Christopher M. Bezeg and Eugene Baek. Partner Michael Mollerus provided tax advice. Partner Kyoko Takahashi Lin and associate Tricia E. Walsh provided executive compensation advice. Counsel David R. Bauer and associate Paul S. Lee provided intellectual property and technology advice. Counsel David A. Zilberberg provided environmental advice. All members of the Davis Polk team are based in the New York office.